HC Wainwright Issues Negative Forecast for TARS Earnings

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) – Equities researchers at HC Wainwright lowered their Q3 2026 earnings estimates for shares of Tarsus Pharmaceuticals in a report issued on Friday, August 7th. HC Wainwright analyst M. Caufield now forecasts that the company will post earnings per share of ($1.50) for the quarter, down from their previous forecast of ($0.17). HC Wainwright has a “Buy” rating and a $88.00 price target on the stock. The consensus estimate for Tarsus Pharmaceuticals’ current full-year earnings is ($1.45) per share. HC Wainwright also issued estimates for Tarsus Pharmaceuticals’ Q4 2026 earnings at ($0.14) EPS, FY2026 earnings at ($2.25) EPS, FY2027 earnings at $0.93 EPS, FY2028 earnings at $2.27 EPS, FY2029 earnings at $3.23 EPS and FY2030 earnings at $4.61 EPS.

A number of other brokerages have also issued reports on TARS. Oppenheimer initiated coverage on Tarsus Pharmaceuticals in a report on Friday, April 24th. They issued an “outperform” rating and a $98.00 price objective for the company. Mizuho cut their target price on Tarsus Pharmaceuticals from $100.00 to $98.00 and set an “outperform” rating on the stock in a research note on Friday, July 31st. Wall Street Zen lowered Tarsus Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Sunday, July 12th. Weiss Ratings reissued a “sell (d-)” rating on shares of Tarsus Pharmaceuticals in a research note on Friday, July 17th. Finally, Guggenheim lowered their price target on Tarsus Pharmaceuticals from $90.00 to $89.00 and set a “buy” rating on the stock in a report on Tuesday, July 21st. Two research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $90.17.

Tarsus Pharmaceuticals Stock Performance

TARS opened at $67.76 on Tuesday. The business’s 50 day moving average is $61.57 and its 200-day moving average is $64.87. The stock has a market cap of $2.97 billion, a PE ratio of -62.16 and a beta of 0.53. The company has a current ratio of 3.20, a quick ratio of 3.17 and a debt-to-equity ratio of 0.21. Tarsus Pharmaceuticals has a twelve month low of $47.60 and a twelve month high of $85.25.

Tarsus Pharmaceuticals (NASDAQ:TARS) last posted its earnings results on Thursday, August 6th. The company reported ($0.43) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.24). Tarsus Pharmaceuticals had a negative net margin of 7.67% and a negative return on equity of 13.53%. The firm had revenue of $173.91 million for the quarter, compared to analyst estimates of $169.65 million.

Hedge Funds Weigh In On Tarsus Pharmaceuticals

Several large investors have recently made changes to their positions in TARS. Parallel Advisors LLC grew its stake in shares of Tarsus Pharmaceuticals by 139.2% in the 1st quarter. Parallel Advisors LLC now owns 500 shares of the company’s stock worth $35,000 after purchasing an additional 291 shares during the last quarter. PNC Financial Services Group Inc. lifted its stake in Tarsus Pharmaceuticals by 367.1% during the first quarter. PNC Financial Services Group Inc. now owns 710 shares of the company’s stock valued at $50,000 after purchasing an additional 558 shares during the last quarter. Comerica Bank lifted its stake in Tarsus Pharmaceuticals by 470.0% during the fourth quarter. Comerica Bank now owns 855 shares of the company’s stock valued at $70,000 after purchasing an additional 705 shares during the last quarter. Truvestments Capital LLC boosted its holdings in Tarsus Pharmaceuticals by 106.1% during the fourth quarter. Truvestments Capital LLC now owns 909 shares of the company’s stock worth $74,000 after buying an additional 468 shares in the last quarter. Finally, Rockefeller Capital Management L.P. boosted its holdings in Tarsus Pharmaceuticals by 15.5% during the fourth quarter. Rockefeller Capital Management L.P. now owns 1,283 shares of the company’s stock worth $105,000 after buying an additional 172 shares in the last quarter. Institutional investors own 90.01% of the company’s stock.

Insider Transactions at Tarsus Pharmaceuticals

In other news, Director Katherine Goodrich sold 2,954 shares of the company’s stock in a transaction on Monday, June 15th. The stock was sold at an average price of $62.08, for a total value of $183,384.32. Following the completion of the sale, the director owned 2,233 shares in the company, valued at $138,624.64. This represents a 56.95% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Bobak R. Azamian sold 10,000 shares of the firm’s stock in a transaction dated Wednesday, June 17th. The shares were sold at an average price of $61.55, for a total value of $615,500.00. Following the transaction, the chief executive officer directly owned 847,991 shares of the company’s stock, valued at $52,193,846.05. This represents a 1.17% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 39,850 shares of company stock worth $2,452,821 over the last 90 days. 9.64% of the stock is currently owned by corporate insiders.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc is a clinical?stage biopharmaceutical company focused on developing novel therapies for diseases of the eye and ocular surface. The company’s research platform centers on neuro?effector modulation to address underlying disease mechanisms rather than solely treating symptoms. Tarsus’s lead candidate, OC-01 (varenicline solution), is an intranasal formulation in Phase 3 development for the treatment of dry eye disease, a condition affecting millions worldwide and associated with significant patient discomfort and reduced quality of life.

In addition to its dry eye program, Tarsus is advancing preclinical and early?stage programs targeting other ophthalmic indications, including allergic conjunctivitis and retinal disorders.